What is Aether?
Led by CEO and Founder Pavle Jeremi, Aether is an American artificial intelligence enterprise dedicated to the discovery and generation of novel proteins. The company's core competency lies in its Protein Function Model, which utilizes advanced machine learning to predict and create proteins with specific, high-impact functions. Unlike traditional methods that rely on public databases, Aether differentiates itself through a proprietary dataset developed via innovative assay technology and rigorous high-throughput screening processes. This technical moat allows the firm to operate at the forefront of synthetic biology, providing solutions that address complex challenges in healthcare, materials science, and beyond. Aether's market position is defined by its commitment to deep-tech integration, positioning it as a key player in the next generation of biotech infrastructure.
How much funding has Aether raised?
Aether has raised a total of $64.2M across 3 funding rounds:
Debt
$150K
Series A
$49M
Other Financing Round
$15M
Debt (2020): $150K with participation from PPP
Series A (2023): $49M led by Trevor Zimmerman and Jay Zaveri
Other Financing Round (2025): $15M supported by Tribe Management, Henkel Ventures, 4DX Ventures, and Shrug Capital
Key Investors in Aether
Tribe Management
A $1.8B AUM venture capital firm based in Menlo Park that specializes in leveraging AI and data science to strategically deploy capital into N-of-1 companies.
Henkel Ventures
The corporate venture capital arm of Henkel, focusing on providing funding and strategic partnerships to early-stage startups with a focus on sustainability and digitalization.
4DX Ventures
An early-stage venture capital firm established in 2017 that maintains a specialized focus on the African technology ecosystem.
What's next for Aether?
With the successful closure of this major strategic investment, Aether is well-positioned to accelerate its research and development roadmap. The company is expected to focus on expanding its proprietary dataset and refining its Protein Function Model to handle increasingly complex biological tasks. Furthermore, the influx of capital will likely support the scaling of its high-throughput screening infrastructure, enabling faster iteration cycles for protein discovery. As Aether moves into this next phase of growth, the focus will shift toward commercializing its protein designs through strategic partnerships and internal product development. The company's trajectory suggests a transition from foundational research to the deployment of high-value, AI-generated biological assets, solidifying its role as a leader in the computational protein engineering sector.
See full Aether company page
